Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Novaliq GmbH. (5/2/12). "Press Release: Novaliq Receives €3.9 Million in further Round of Financing Talks". Heidelberg.

Organisations Organisation Novaliq GmbH
  Group HOPP Group (family of Dietmar Hopp)
  Organisation 2 Dievini Hopp BioTech Holding GmbH & Co. KG
  Group HOPP Group (family of Dietmar Hopp)
Products Product CyclASol
  Product 2 venture capital
Index term Index term Novaliq–Hopp Group: investment, 201205 financing round €3.9m from Dievini Hopp BioTech Holding GmbH & Co KG
Persons Person Günther, Bernhard (Novaliq GmbH 200701– Managing Director before Fluoron GmbH Managing Director)
  Person 2 Hopp, Dietmar (SAP)
     


Novaliq GmbH, a drug delivery company focusing on difficult to dissolve substances for ophthalmic and dermatological applications, announced the conclusion of a round of financing talks resulting in €3.9 million.

Since initial financing in 2007, the company has been able to collect funding amounting to a total of 13.2 million Euros in four rounds of financing talks. The sole investor is once again the investment company of SAP co-founder Dietmar Hopp, dievini Hopp Bio Tech holding GmbH & Co. KG. With the fresh capital, the company plans to take its lead projects far into the clinical development phase.

"We are very pleased indeed about the continued confidence shown by our investor to ensure our liquidity until 2013", said Bernhard Günther, Managing Director of Novaliq. "By then, we expect to successfully conclude a clinical Phase II proof-of-concept study with our main project "CyclAsol". In addition, other ophthalmic formulations are to enter the clinical study stage during this period".


About Novaliq

Novaliq is a drug delivery company that develops innovative pharmaceutical formulations. Novaliq's patented semifluorinated alkanes (SFAs) can be used in different forms of application to transport drugs and oxygen for therapeutic purposes. Apart from ophthalmic and dermatological formulations, Novaliq is currently developing oxygen carriers for organ conservation and has a number of product candidates with excellent market potential in preclinical and clinical stages of development.


If you have any questions, please contact:

Bernhard Günther, Dipl. Ing. (FH), Managing Director,
Novaliq GmbH, Fon: +49 (0) 6221/5 02 59-10
Email: info[at]novaliq.de

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for HOPP Group (family of Dietmar Hopp)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top